Toni M. Brand, Ph.D.
Affiliations: | 2014 | Cellular & Molecular Pathology | University of Wisconsin, Madison, Madison, WI |
Area:
Cell Biology, Oncology, PharmacologyGoogle:
"Toni Brand"Mean distance: (not calculated yet)
Parents
Sign in to add mentorDeric L. Wheeler | grad student | 2014 | UW Madison | |
(Investigations of nuclear HER family receptors in cancer and resistance to cetuximab therapy.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Brand TM, Iida M, Corrigan KL, et al. (2021) Retraction. Science Signaling. 14: eabn0168 |
Brand TM, Iida M, Dunn EF, et al. (2019) Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer. Molecular Cancer Therapeutics. 18: 868 |
Iida M, Brand TM, Campbell DA, et al. (2018) Correction: Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene |
Brand TM, Iida M, Stein AP, et al. (2018) Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 6099 |
Brand TM, Iida M, Luthar N, et al. (2018) Corrigendum to: "Nuclear EGFR as a molecular target in cancer" [Radiother Oncol 108 (2013) 370-77]. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology |
Frazier NM, Brand T, Gordan JD, et al. (2018) Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene |
Leonard B, Brand TM, O'Keefe RA, et al. (2018) BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC. Cancer Research |
Brand TM, Iida M, Corrigan KL, et al. (2017) The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Science Signaling. 10 |
Brand T, Zeng Y, Leonard B, et al. (2017) Abstract 95: Targeting BRD4 overcomes cetuximab resistance in HNSCC Cancer Research. 77: 95-95 |
Black NK, Iida M, Rodems TS, et al. (2017) Abstract 4176: Targeting TAM family members with antibody or small molecule inhibitors enhances therapeutic modalities of HNSCC Cancer Research. 77: 4176-4176 |